Thomas W. Beetham

Thomas W. Beetham is a declared insider at 2 companies; the most frequent names are Dianthus Therapeutics, Inc. /DE/ and Viridian Therapeutics, Inc.\DE. We count 7 filings; the first trade dates from 14 September 2021 and the latest from 3 March 2026.

On the open market, the record shows 1 purchase worth €105k and 1 sale worth €35k. Purchases outweigh sales by €70k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants and 1 option exercise.

The record was last updated on 9 March 2026 with a share grant (€79k) in Viridian Therapeutics, Inc.\DE. The last insider purchase was made public on 30 September 2024, 748 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.